Navigation Links
ChemoBrain: How cancer therapies can affect your mind

While surviving cancer should be an occasion for rejoicing, many people who have undergone the standard or high-dose chemotherapy to defeat the disease unfortunately suffer from a physical and mental ailment known as "chemobrain." This cognitively dysfunctional symptom ranges from fatigue and memory loss to serious learning impairment due to possible brain damage. In CHEMOBRAIN: HOW CANCER THERAPIES CAN AFFECT YOUR MIND (Prometheus Books, $18.98), a clear, concise guide for cancer patients, survivors, families, friends, and caregivers, noted science journalist Ellen Clegg provides the latest information on this much-discussed but poorly understood side effect of chemotherapy treatment, while alsoin an objective journalistic fashiongiving voice to those medical professionals who remain skeptical of chemobrain.

Based on extensive and candid interviews with both those suffering from chemobrain and the physicians and scientists who have treated and studied this problem, Clegg cuts through the scientific jargon and explains in understandable terms how chemotherapy works at the most basic biological level. In doing so, she provides cancer survivors with the knowledge to understand what is happening to them and practical tips for coping with the aftermath of chemotherapy treatment.

Clegg's extensive cross-analysis of chemotherapy survivors' stories with the opinions of doctors who recognize the symptoms will provide the affirmation that so many who suffer from chemobrain so desperately need. She includes tactics for dealing with cognitive problems and other lingering side effects, strategies for multitasking at home and reentering the workforce, and even ways to deal with health insurance.

In addition to personal strategies and stories, Clegg also provides the history of the patient empowerment movement that brought chemobrain to the attention of the medical establishment in the first place. She also addresses the future of cancer research and the search for treatments that do less harm, and looks at chemobrain's implications for the mental health of developing children.

Stewart B. Fleishman, MD, Director, Supportive Services, Continuum Cancer Centers of New York: Beth Israel and St. Luke's-Roosevelt Hospitals, is a doctor at the forefront of a new movement to treat cognitive dysfunction as a real symptom with real potential solutions. "We will learn more about the causes of cognitive impairment soon, asking future patient generations to invest less of their quality of life to not only survive, but also thrive after diagnosis of cancer and its treatment," he writes in the book's foreword. "Many questions have yet to be answered. Further studies are now underway to do so."

While survivor circles have acknowledged and debated chemobrain for years, this is the first and only book to delve into the cognitive problems many patients endure when they undergo chemotherapy. CHEMOBRAIN brings together cutting-edge science, the compelling stories of adults and children who have struggled for years with cognitive dysfunction, and the coping strategies being developed on the front lines of patient care. Clegg's investigative study of chemobrain is both a required read for today's upcoming medical professionals and a gospel for those suffering with this widespread symptom as well as for caring family members.

About the Author: Ellen Clegg (Boston, MA) is a deputy managing editor of news operations at the Boston Globe, in charge of the Sunday paper. Her previous positions at the same paper include health and science editor, night news editor, and city editor.


Contact: Jill Maxick
Prometheus Books

Related biology news :

1. Safeway gives $685,000 to TGen for breast cancer research
2. MIT student develops new innovations to selectively kill cancer cells
3. U-M researchers ID gene involved in pancreatic cancer
4. Newly discovered gene plays vital role in cancer
5. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
6. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators
7. Lowering your cholesterol may decrease your risk of cancer
8. New technique for cancer screening
9. Suppressing cancer with a master control gene
10. Link between unexploded munitions in oceans and cancer-causing toxins determined
11. Researchers identify gene linked to aggressive progression of liver cancer
Post Your Comments:
Related Image:
ChemoBrain: How cancer therapies can affect your mind
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: